Acelyrin, Inc. (NASDAQ:SLRN) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants Tyler Marciniak - VP of Investor Relations, Communications, and Corporate Operations Shao-Lee Lin - Founder and Chief Executive Officer Paul Peloso - Chief Medical Officer Gil Labrucherie - Interim Chief Financial Officer Conference Call Participants Tyler Van Buren - TD Cowen Akash Tewari - Jefferies Vikram Purohit - Morgan Stanley Operator Good afternoon and welcome to the ACELYRIN, INC. Confere ...

Table of Contents x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Delaware 85-2406735 (S ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to_____. Commission File Number: 001-41696 ACELYRIN, INC. (Exact name of registrant as specified in its charter) Delaware 85-2406735 ( ...